Krystal Biotech (KRYS) Common Equity (2016 - 2026)

Krystal Biotech has disclosed Common Equity across 11 years of filings, most recently posting $1.3 billion for Q1 2026.

• Common Equity for Q1 2026 came in at $1.3 billion, up 29.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 29.66% YoY), and the FY2025 annual result was $1.2 billion, up 28.87% from the prior year.
• Common Equity came in at $1.3 billion for Q1 2026 at Krystal Biotech, up from $1.2 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.3 billion in Q1 2026 to a low of $489.6 million in Q1 2023.
• The 5-year median for Common Equity is $799.2 million (2024), against an average of $822.2 million.
• Across the five-year window, Common Equity retreated 12.02% in 2022 and soared 63.26% in 2024, its largest moves.
• Krystal Biotech's Common Equity stood at $522.2 million in 2022, then jumped by 49.1% to $778.6 million in 2023, then grew by 21.54% to $946.4 million in 2024, then gained by 28.87% to $1.2 billion in 2025, then climbed by 4.69% to $1.3 billion in 2026.
• The last three Common Equity figures came in at $1.3 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.